NeuMoDx COVID-19 multiplex test gets EUA

Create PDF

July 2021—Qiagen announced FDA emergency use authorization for the NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay, to help identify and differentiate people suspected of respiratory viral infection consistent with COVID-19.

The multiplex PCR test detects and differentiates influenzas A and B, respiratory syncytial virus, and SARS-CoV-2 infections within 80 minutes.